Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibit and Consolidated Financial Statement Schedules
(a)
The following documents are filed as part of this Annual Report:
Consolidated Financial Statements. See Index to Consolidated Financial Statements in Part II Item 8 of this Annual Report.
Consolidated Financial Statement Schedules. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the requested information is included in the financial statements or notes thereto.
Exhibits. The following is a list of exhibits filed with this Annual Report or incorporated herein by reference:
| Incorporation by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber · ExhibitDescription · Form · File No. · Exhibit · FilingDate · FiledHerewith | |||||
| 1.1 | Sales Agreement by and between Registrant and TD Securities (USA) LLC, dated January 6, 2025. | S-3 | 333-284146 | 1.2 | 1/6/2025 |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8‑K | 001‑39712 | 3.1 | 11/23/2020 |
| 3.2 | Amended and Restated Certificate of Bylaws. | 8‑K | 001‑39712 | 3.1 | 12/16/2022 |
| 4.1 | Form of Common Stock Certificate. | S‑1 | 333‑249748 | 4.1 | 10/30/2020 |
| 4.2 | Description of Capital Stock. | 10-K | 001‑39712 | 4.3 | 3/17/2021 |
| 4.3 | Form of Pre-Funded and ExchangeWarrant | 8-K | 001-39712 | 4.1 | 12/2/2024 |
| 4.4 | Form of Exchange Warrant | 8-K | 001-39712 | 4.1 | 1/10/2025 |
| 10.1# | Olema Pharmaceuticals, Inc. 2014 Stock Plan, as amended. | S‑1 | 333‑249748 | 10.1 | 10/30/2020 |
| 10.2# | Forms of Stock Option Grant Notice, Stock Option Agreement, Early Exercise Stock Purchase Agreement and Notice of Exercise and Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the Olema Pharmaceuticals, Inc. 2014 Stock Plan. | S‑1 | 333‑249748 | 10.2 | 10/30/2020 |
| 10.3# | Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan. | S‑1/A | 333‑249748 | 10.3 | 11/16/2020 |
| Incorporation by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | ExhibitDescription | Form | File No. | Exhibit | FilingDate | FiledHerewith |
| 10.4# | Forms of Stock Option Grant Notice and Stock Option Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan. | S‑1 | 333‑249748 | 10.4 | 10/30/2020 | |
| 10.5# | Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan. | S‑1 | 333‑249748 | 10.5 | 10/30/2020 | |
| 10.6# | Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. | S‑1/A | 333‑249748 | 10.6 | 11/16/2020 | |
| 10.7# | Olema Pharmaceuticals, Inc. 2020 Non-Employee Director Compensation Policy. | S‑1/A | 333‑249748 | 10.7 | 11/16/2020 | |
| 10.8# | Form of Indemnification Agreement by and between the Registrant and its directors and executive officers. | S‑1 | 333‑249748 | 10.8 | 10/30/2020 | |
| 10.9# | Amended and Restated Offer Letter by and between the Registrant and Sean Bohen, dated November 13, 2020. | S‑1/A | 333‑249748 | 10.9 | 11/16/2020 | |
| 10.10# | Amended and Restated Offer Letter by and between the Registrant and Shane Kovacs, dated November 13, 2020. | S‑1/A | 333‑249748 | 10.12 | 11/16/2020 | |
| 10.11# | Amended and Restated Offer Letter by and between the Registrant and David Myles, dated November 13, 2020. | S‑1/A | 333‑249748 | 10.14 | 11/16/2020 | |
| 10.12¥ | Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated January 13, 2022. | 10-Q | 001-39712 | 10.1 | 5/9/2023 | |
| 10.13 | Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated October 9, 2023. | 8-K | 001-39712 | 10.1 | 10/10/2023 | |
| 10.14# | Olema Pharmaceuticals, Inc. 2022 Inducement Plan, as amended December 5, 2024. | X | ||||
| Incorporation by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | ExhibitDescription | Form | File No. | Exhibit | FilingDate | FiledHerewith |
| 10.15# | Form of Stock Option Agreement and Option Grant Notice under the Inducement Plan. | 10-K | 001-39712 | 10.18 | 2/28/2022 | |
| 10.16# | Offer Letter by and between the Registrant and Naseem Zojwalla, dated December 15, 2021. | 10-K | 001-39712 | 10.19 | 2/28/2022 | |
| 10.17¥ | Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Discovery Technologies Limited, dated June 7, 2022. | 10-Q | 001-39712 | 10.1 | 8/9/2022 | |
| 10.18# | Offer Letter by and between the Registrant and Shawnte Mitchell, dated January 27, 2025 | X | ||||
| 10.19 | Stock Purchase Agreement by and among the Registrant and the Purchasers named therein, dated September 5, 2023. | 8-K | 001-39712 | 10.1 | 9/5/2023 | |
| 10.20 | Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated September 5, 2023. | 8-K | 001-39712 | 10.2 | 9/5/2023 | |
| 10.21 | Amendment No. 2 to Amended andRestated Clinical Collaboration andSupply Agreement by and betweenthe Registrant and Novartis Institutesfor BioMedical Research, Inc., datedMarch 22, 2024. | 10-Q | 001-39712 | 10.1 | 5/8/2024 | |
| 10.22 | First Amendment to Loan andSecurity Agreement by and betweenthe Registrant and Silicon Valley Bank, a division of First-Citizens Bank& Trust Company, dated June 28,2024. | 10-Q | 001-39712 | 10.1 | 8/6/2024 | |
| 10.23# | Olema Pharmaceuticals, Inc.Amended and RestatedNon-Employee DirectorCompensation Policy. | 10-Q | 001-39712 | 10.2 | 8/6/2024 | |
| Incorporation by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | ExhibitDescription | Form | File No. | Exhibit | FilingDate | FiledHerewith |
| 10.24 | Form of Securities PurchaseAgreement by and among theRegistrant and the Purchasers namedtherein, dated November 29, 2024. | 8-K | 001-39712 | 10.1 | 12/2/2024 | |
| 10.25¥ | Clinical Trial Collaboration and SupplyAgreement by and between theRegistrant and Novartis Pharma AG,dated November 29, 2024. | X | ||||
| 10.26¥ | Amendment Number No. 1 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated May 2, 2024 | X | ||||
| 10.27¥ | Amendment Number No. 2 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated November 15, 2024 | X | ||||
| 19.1 | Olema Pharmaceuticals, Inc. Insider Trading Policy | X | ||||
| 21.1 | Subsidiaries of the Registrant. | 10-K | 001-39712 | 21.1 | 3/11/2024 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | ||||
| 24.1 | Power of Attorney (included on the Signatures page of this Annual Report on Form 10‑K). | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| Incorporation by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber · ExhibitDescription · Form · File No. · Exhibit · FilingDate · FiledHerewith | |||||
| 32.1† · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | |||||
| 32.2† · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | |||||
| 97.1 | Incentive Compensation Recoupment Policy. | 10-K | 001-39712 | 97.1 | 3/11/2024 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | |||
| 104 | Cover Page formatted as Inline XBRL and contained in Exhibit 101 | X | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.